Definitive Contract HHSN268201000042C
Award Date 8/10/10
Potential Completion Date 5/28/11
Potential Value $150K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $747,441.00 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute to Avantgen Inc., a small business based in San Diego, CA. The contract is for a Small Business Innovation Research (SBIR) Phase II project titled "Recombinant Antibodies as Affinity Captures" under Topic 288. The goal is to develop recombinant antibodies for use in affinity capture applications. This contract builds upon Avantgen's prior SBIR Phase I and II awards from the National...
- This $199,987 fixed-price contract was awarded by the National Cancer Institute, a component of the National Institutes of Health, to Avantgen Inc., a small business biotechnology company based in San Diego, California. The contract is for the development of recombinant rabbit monoclonal antibodies to be used as affinity captures for peptides. This work supports the agency's research and development efforts in cancer immunotherapy. The contract was set aside for small businesses and has a period...
- This is a $356,021 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services' National Institutes of Health (NIH), to Avantgen Inc., a San Diego-based biotechnology company. The contract is for the development of rabbit monoclonal antibodies for ferret biomarkers. This work is set aside for small businesses. Avantgen has previously received NIH contracts to develop rapid diagnostic...
- This is a $1,497,384.00 firm fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Avantgen Inc., a small business biotechnology company based in San Diego, California. The contract is for the development of rabbit monoclonal antibodies for use as ferret biomarkers. This contract is not associated with a larger contract vehicle and does not have a set-aside designation. Avantgen Inc. has previously been awarded multiple federal...
- This definitive contract was awarded by the National Institutes of Health National Cancer Institute to Avantgen Inc. for $299,854 to develop and validate non-mouse reagents to enable preclinical development of novel therapeutics under the Small Business Innovation Research Program Phase I solicitation. The contract responds to the research topic "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics" listed in the NIH/CDC SBIR Contract...
- This is a $592,751 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Avantgen Inc., a San Diego-based biotechnology company. The contract is for the development of rabbit monoclonal antibodies to serve as biomarkers for the Indian Flying Fox (bat) virus. There is no set-aside designation for this contract. Avantgen has previously worked with NIAID and other federal agencies on the development of rapid test kits,...
- This $300,000.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the Department of Health and Human Services' (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Avantgen Inc., a small biotechnology company based in San Diego, California. The contract is for the development of a rapid and point-of-care diagnostic kit for the detection of the hepatitis C virus. This award is part of NIAID's solicitation for...
- This federal contract award was made by the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and other scientific research products based in San Diego, California. The $10,492.50 firm-fixed-price purchase order is for the delivery of Total-Seq antibody cocktails, which are mixtures of antibodies conjugated to DNA oligonucleotides used in the preparation of...
- This is a federal contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services (HHS), to A&G Pharmaceutical, Inc. (doing business as Precision Antibody). The $199,380 firm-fixed-price contract is for research and development related to biomedical products and was awarded on September 14, 2012, with a completion date of September 13, 2013. The contract does not have a set-aside designation. A&G Pharmaceutical, Inc. is a...
- This federal contract was awarded by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health (NIH), to A&G Pharmaceutical, Inc. (also known as Precision Antibody), a for-profit manufacturer of biological materials and research services. The contract, valued at $999,685.00, is for the development of "SMART FUSION: HIGH AFFINITY PEPTIDE CAPTURE REAGENTS" and has a period of performance through March 31, 2018. The contract type is a Definitive...